Assessing the Heart Benefits of Ertugliflozin

The results from a major trial examining whether the diabetes drug ertugliflozin (brand name STEGLATRO), the VERTIS-CV trial, suggest that ertugliflozin is not superior to placebo in reducing major adverse cardiovascular events (MACE) but may reduce the rate of hospitalization for heart failure.  Read more

Posted in Drugs